Business
CROSSJECT presents its financial results and key highlights for the first half of 2025
Press release CROSSJECT presents its financial results and key highlights for the first half of 2025 Cash position: €6.3 million, compared to €7.0 million as of December 31 2024, demonstrating the Company's excellent control of its resources. Stable R&D investments and a €3.1 million increase in R&D reimbursements from BARDA1 for the first half of 2024, to €6.5 million, in line with the focus on regulatory development and batch manufacturing related to the registration of ZEPIZURE®.The company c
About this update from Crossject Sa
[{"type":"image","alt":"CROSSJECT","displaySize":"","headline":null,"caption":"CROSSJECT","className":"","disableSlideshowImg":false,"size":{"original":{"width":200,"height":87,"url":"https://media.zenfs.com/en/globenewswire.com/5049eda363ac301cbfd1577dab53d65a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rK9m607pcnIrkhBB4D_IFA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTE1NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5049eda363ac301cbfd1577dab53d65a","width":200,"height":87}},"lazy":false},{"type":"text","content":"Press release","length":13,"tagName":"p"},{"type":"text","content":"CROSSJECT presents its financial results and key highlights for the first half of 2025","length":86,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Cash position: €6.3 million, compared to €7.0 million as of December 31 2024, demonstrating the Company's excellent control of its resources.","length":145,"tagName":"p"}]},{"val":[{"type":"text","content":"Stable R&D investments and a €3.1 million increase in R&D reimbursements from BARDA1 for the first half of 2024, to €6.5 million, in line with the focus on regulatory development and batch manufacturing related to the registration of ZEPIZURE®.","length":252,"tagName":"p"}]},{"val":[{"type":"text","content":"The company continued to make progress toward BARDA's submission of its Emergency Use Authorization (EUA) application for ZEPIZURE®. ","length":136,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":533,"olType":false},{"type":"text","content":"Dijon, France, September 24, 2025 10:00 p.m. CET -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceutical company developing products for emergency situations based on its proprietary ZENEO® needle-free auto-injector technology, today announced its financial results for the first half of the year ended June 30, 2025, and provided an update on its business highlights for the first half of 2025.","length":417,"tagName":"p"},{"type":"text","content":"During this period, CROSSJECT continued its regulatory activities in conjunction with the U.S. Biomedical Advanced Research and Development Authority (BARDA) with the aim of obtaining regulatory approvals for ZEPIZURE® in the United States as soon as possible.","length":260,"tagName":"p"},{"type":"text","content":"In this context, in June, and as announced ...